Culturally tailored yoga program for cancer patients undergoing stem cell transplantation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to develop and assess a culturally sensitive yoga therapy program specifically designed for patients undergoing hematopoietic stem cell transplantation (HSCT) in India, Tanzania, and the United States. The program will be informed by semi-structured interviews with patients to understand cultural norms and preferences related to yoga and psychosocial support. Participants will engage in yoga sessions two weeks prior to their transplant and continue for 30 days post-transplant, with sessions offered in person or via telehealth. The study will also evaluate the feasibility of patient adherence and follow-up completion.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Cancer patients scheduled to undergo an autologous or allogeneic HSCT at MD Anderson, HCG, or MNH;
2. Age 18 or older;
3. English, Hindi, or Swahili speaking;
4. Able to sign a written informed consent and be willing to follow protocol requirements.

Exclusion Criteria:

* Extreme mobility issues that preclude participating in the YT;
* Major thought disorders such as schizophrenia or uncontrolled bipolar disorder;
* HCT comorbidity score of 3 or higher, excluding cancer diagnoses

Where it's running

• M D Anderson Cancer Center
  Houston, Texas, United States Recruiting
• Swami Vivekananda Yoga Anusandhana Samsthana
  Giddenahalli, Karnataka, India Recruiting
• Muhimbili National Hospital
  Dar es Salaam, Tanzania Recruiting

Study contacts

• Principal investigator: Lorenzo Cohen, PHD — M.D. Anderson Cancer Center
• Study coordinator: Lorenzo Cohen, PHD
• Email: lcohen@mdanderson.org
• Phone: (713) 745-4260

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Population PK-guided ATG Dosing in Haploidentical Stem Cell Transplant

  This trial tests a population PK-guided ATG dosing strategy in people undergoing haploidentical hematopoietic stem cell transplantation to see if it improves outcomes.

  Recruiting Phase 3 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07862127

• Population PK-guided ATG Dosing in Haplo-HSCT

  This study tests a population PK-guided dosing strategy for anti-thymocyte globulin (ATG) in adults and adolescents undergoing haploidentical stem cell transplantation to see if it can reduce GVHD while keeping relapse risk acceptable.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07791576

• Low-dose liposomal amphotericin B to prevent invasive fungal infections in neutropenic children

  This study tests whether giving a fixed low dose of liposomal amphotericin B can prevent invasive fungal infections in children aged 3–17 who are severely neutropenic after hematopoietic stem cell transplantation or similar high-risk conditions.

  Recruiting Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Haikou, Hainan · NCT07725263

• Personalized ATG dosing in unrelated donor stem cell transplants

  This trial tests whether tailoring anti-thymocyte globulin dosing works better than standard fixed dosing in adults and adolescents receiving unrelated donor stem cell transplants.

  Recruiting Phase 4 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07648992

• Hematologic cancer survivors after stem cell transplant try a personalized care plan

  This study tests a personalized Survivorship Care Plan for people with hematologic cancer who have undergone a stem cell transplant to see if it’s feasible within the Italian health system.

  Recruiting Azienda USL Reggio Emilia - IRCCS · Reggio Emilia · NCT07579065

• T-cell–guided letermovir stopping after allogeneic stem cell transplant

  This tests whether using a CMV-specific T-cell blood test to decide when adult CMV-positive patients can stop letermovir after allogeneic stem cell transplant keeps them protected while avoiding unnecessary drug exposure.

  Recruiting Phase 4 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Beijing, Beijing Municipality and 11 other locations · NCT07569653

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.